The granting of a patent typically provides a company with exclusive rights to their intellectual property, which can prevent competition and potentially lead to market exclusivity. For Windtree Therapeutics, this European patent could enhance the company's ability to protect its SERCA2a activator drug candidates, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.